Heterozygous loss of platelet glycoprotein (GP) Ib-V-IX variably affects platelet function in velocardiofacial syndrome (VCFS) patients

Summary

Velocardiofacial syndrome (VCFS) is a common, phenotypically heterogeneous developmental disorder caused by an interstitial microdeletion within human chromosome 22q11. The deleted chromosomal region in >90% of VCFS patients includes the GPIbβ gene, encoding for one subunit of the platelet GPIb-V-IX receptor, which is critical for platelet adhesion under shear, and important in aggregation and thrombin-mediated activation. Complete loss of GPIb-V-IX due to autosomal recessive inheritance of two GPIbα,Ibβ or GP9 gene mutations,results in a severe bleeding disorder,Bernard-Soulier syndrome (BSS). In this study, twenty-one confirmedVCFS patients were analyzed for platelet morphological and functional alterations, resulting from the heterozygous loss of one GPIbβ gene allele. Compared to unaffected family members,VCFS patients showed a significant decrease in platelet count; VCFS platelet size and mean platelet volume were increased, but not as markedly as in BSS. As expected from obligatory heterozygotes for GPIbβ deficiency, VCFS patients showed reduced platelet GPIb-V-IX surface expression and total GPIb content, but with considerable variation between cases. Platelet function tested using the PFA-100^™ analyzer was impaired in 70% of patients. Platelet aggregation was reduced in response to a GPIb-dependent agonist, ristocetin, in 50% ofVCFS patients, with 35% showing a reduced response to thrombin receptor activating peptide. Genomic screening was performed to exclude mutations of the subunit genes, indicating that these platelet abnormalities were due to GPIbβ heterozygosity and not spontaneous BSS. In conclusion, many VCFS patients have in-vitro defects in platelet function that may increase their risk of bleeding during surgery.

Keywords

GPIb - platelet function - inherited platelet disorder - velocardiofacial syndrome

• References

• 1 Lindsay EA. Chromosomal microdeletions: Dissecting del22q11 syndrome. Nat Rev Genet 2001; 2: 858-868.
• 2 McQuade L, Christodoulou J, Budarf M. et al. Patient with a 22q11.2 deletion with no overlap of the minimal DiGeorge syndrome critical region (MDGCR). Am J Med Genet 1999; 86: 27-33.
• 3 Yamagishi H, Srivastava D. Unraveling the genetic and developmental mysteries of 22q11 deletion syndrome. Trends Mol Med 2003; 9: 383-389.
• 4 Scambler PJ. The 22q11 deletion syndromes. Hum Mol Genet 2000; 9: 2421-2426.
• 5 Sandrin-Garcia P, Macedo C, Martelli LR. et al. Recurrent 22q11.2 deletion in a sibship suggestive of parental germline mosaicism in velocardiofacial syndrome. Clin Genet 2002; 61: 380-383.
• 6 Cuneo BF. 22q11.2 deletion syndrome: DiGeorge, velocardiofacial, and conotruncal anomaly face syndromes. Curr Opin Pediatr 2001; 13: 465-472.
• 7 Henwood J, Pickard C, Leek JP. et al. A region of homozygosity within 22q11.2 associated with congenital heart disease: Recessive DiGeorge/velocardiofacial syndrome?. J Med Genet 2001; 38: 533-536.
• 8 Pallotta R, Evangelista V, Margaglione M. et al. Macrothrombocytopenia in velocardiofacial syndrome. J Thromb Haemost 2005; 3: 601-603.
• 9 Berndt MC, Shen Y, Dopheide SM. et al. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001; 86: 178-188.
• 10 Adam F, Bouton M-C, Huisse M-G. et al. Thrombin interaction with platelet membrane glycoprotein Ibβ. Trends Mol Med 2003; 9: 461-464.
• 11 Celikel R, McClintock RA, Roberts JR. et al. Modulation of α-thrombin function by distinct interactions with platelet glycoprotein Ibβ. Science 2003; 301: 218-221.
• 12 López JA, Andrews RK, Afshar-Kharghan V. et al. Bernard-Soulier syndrome. Blood 1998; 91: 4397-4418.
• 13 Budarf ML, Konkle BA, Ludlow LB. et al. Identification of a patient with Bernard-soulier syndrome and a deletion in the DiGeorge/velo-cardio-facial chromosomal region in 22q11.2. Hum Mol Genet 1995; 4: 763-766.
• 14 Kenny D, Morateck PA, Gill JC. et al. The critical interaction of glycoprotein (GP) Ibβ with GPIX – a genetic cause of Bernard-Soulier syndrome. Blood 1999; 93: 2968-2975.
• 15 Ludlow LB, Schick BP, Budarf ML. et al. Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibβ promoter resulting in the Bernard- Soulier syndrome. J Biol Chem 1996; 271: 22076-22080.
• 16 Hillmann A, Nurden A, Nurden P. et al. A novel hemizygous Bernard-soulier syndrome (BSS) mutation in the amino terminal domain of glycoprotein (GP)Ibβ – platelet characterization and transfection studies. Thromb Haemost 2002; 88: 1026-1032.
• 17 Tang J, Stern-Nezer S, Liu P-C. et al. Mutation in the leucine-rich repeat C-flanking region of platelet glycoprotein Ibβ impairs assembly of von Willebrand factor receptor. Thromb Haemost 2004; 92: 75-88.
• 18 Nakagawa M, Okuno M, Okamoto N. et al. Brief clinical report: Bernard-Soulier syndrome associated with 22q11.2 microdeletion. Am J Med Genet 2001; 99: 286-288.
• 19 Iascone MR, Sacchelli M, Vittorini S. et al. Complex conotruncal heart defect, severe bleeding disorder and 22q11 deletion: A new case of Bernard-soulier syndrome and of 22q11 deletion syndrome?. Ital Heart J 2001; 2: 475-477.
• 20 Van Geet C, Devriendt K, Eyskens B. et al. Velocardiofacial syndrome patients with a heterozygous chromosome 22q11 deletion have giant platelets. Pediatr Res 1998; 44: 607-611.
• 21 Shprintzen RJ. Velocardiofacial syndrome. Otolaryngol Clin North Am 2000; 33: 1217-1240.
• 22 Mammen EF, Comp PC, Gosselin R. et al. PFA-100™ system: A new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.
• 23 Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorder: An algorithmic approach. Arch Pathol Lab Med 2002; 126: 133-146.
• 24 McNicol A, Robson CA. Thrombin receptor-activating peptide releases arachidonic acid from human platelets: A comparison with thrombin and trypsin. J Pharmacol Exp Ther 1997; 281: 861-867.
• 25 Fusté B, Díaz-Ricart M, Jensen MK. et al. Trap induces more intense tyrosine phosphorylation than thrombin with differential ultrastructural features. Am J Pathol 2002; 160: 2245-2252.
• 26 Zaffran Y, Meyer SC, Negrescu E. et al. Signaling across the platelet adhesion receptor glycoprotein Ib- IX induces αIIbβ3 activation both in platelets and a transfected Chinese hamster ovary cell system. J Biol Chem 2000; 275: 16779-16787.
• 27 Perrault C, Mangin P, Santer M. et al. Role of the intracellular domains of GPIb in controlling the adhesive properties of the platelet GPIb/V/IX complex. Blood 2003; 101: 3477-3484.
• 28 Yuan Y, Kulkarni S, Ulsemer P. et al. The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J Biol Chem 1999; 274: 36241-36251.
• 29 Gonzalez-Manchon C, Butta N, Iruin G. et al. Disruption of the Cys5-Cys7 disulfide bridge in the platelet glycoprotein Ibβ prevents the normal maturation and surface exposure of GPIb-IX complexes. Thromb Haemost 2003; 90: 456-464.
• 30 Kurokawa Y, Ishida F, Kamijo T. et al. A missense mutation (Tyr88 to Cys) in the platelet membrane glycoprotein Ibβ gene affects GP Ib/IX complex expression. Thromb Haemost 2001; 86: 1249-1256.
• 31 Moran N, Morateck PA, Deering A. et al. Surface expression of glycoprotein Ibβ is dependent on glycoprotein Ibβ: Evidence from a novel mutation causing Bernard-Soulier syndrome. Blood 2000; 96: 532-539.
• 32 Watanabe D, Barlow DP. Random and imprinted monoallelic expression. Genes Cells 1996; 1: 795-802.
• 33 Maynard TM, Haskell GT, Lieberman JA. et al. 22q11 DS: Genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome. Int J Dev Neurosci 2002; 20: 407-419.